Omeprazole, one of the most widely used medications worldwide, is generally safe for short courses but carries a growing list of concerns when taken for months or years. These range from nutrient deficiencies and increased infection risk to subtler effects on bones, kidneys, and the gut microbiome. None of them are guaranteed outcomes, and for many people the benefits of staying on omeprazole genuinely outweigh these risks. But the drug was originally designed for short-term use, and the gap between that intent and how millions of people actually take it has prompted a lot of research into what happens when acid suppression becomes a long-term commitment.
Why Long-Term Use Changes the Risk Picture
Omeprazole belongs to the proton pump inhibitor (PPI) family. It works by permanently disabling the acid-producing pumps on the surface of stomach cells. The drug itself clears your bloodstream within hours, but because it bonds irreversibly to those pumps, acid suppression lasts until your body builds new ones, which takes a day or two.1PubMed Central. Pharmacology of proton pump inhibitors That is what makes it so effective for heartburn and ulcers. It is also what makes long-term use a different proposition from popping an antacid: you are not just neutralizing acid in the moment, you are fundamentally lowering the baseline acidity of your stomach around the clock.
Stomach acid is not just there to cause heartburn. It helps you absorb minerals and vitamins, kills off bacteria you swallow with food, and keeps the microbial population of your upper gut in check. When that acid barrier stays suppressed for months or years, downstream consequences start accumulating. Most of the side effects discussed below trace back to this single upstream change: chronically reduced stomach acidity.
Nutrient Deficiencies That Build Over Time
Your stomach needs acid to pry certain nutrients loose from food so they can be absorbed. The three that come up most often with long-term omeprazole use are vitamin B12, iron, and magnesium.
Vitamin B12 requires acid to be released from the proteins in food. In one study of elderly patients on prolonged acid suppression, roughly half were either deficient or had insufficient B12 levels.2PubMed. Effect of long-term acid suppression therapy with proton pump inhibitors or H(2) receptor blockers on serum vitamin B(12) levels in elderly population That is a striking number, though it is worth noting the deficiency did not differ much between different types of acid-suppressing drugs in that particular study. A separate cohort study found that omeprazole users had notably lower B12 levels compared to those on pantoprazole, another PPI.3PubMed Central. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study B12 deficiency creeps up slowly and can cause fatigue, nerve tingling, memory problems, and anemia. If you have been on omeprazole for more than a year, asking your doctor to check your B12 level is reasonable.
Iron absorption also depends on stomach acid, which converts dietary iron into a form the gut can take up. Case reports have documented iron deficiency anemia tied directly to long-term PPI use, with the deficiency resolving after the drug was stopped.4PubMed Central. Iron Deficiency Anemia Due to the Long-term Use of a Proton Pump Inhibitor This is more likely to matter for people who are already borderline on iron, such as menstruating women or those with limited dietary intake.
Magnesium is a less intuitive one: it is not just about acid-mediated absorption. Long-term PPI use can reduce magnesium levels through a combination of decreased intestinal absorption and increased kidney losses. Low magnesium can cause muscle cramps, heart rhythm changes, and, as discussed below, weakened bones.5PubMed Central. Osseous implications of proton pump inhibitor therapy: An umbrella review
Bone Health and Fracture Risk
Multiple reviews have found a statistical link between long-term PPI use and increased fracture risk, particularly hip fractures in older adults. The exact mechanism is still debated, but researchers have proposed several pathways: impaired calcium absorption from lower stomach acid, elevated gastrin levels that interfere with bone remodeling, and the magnesium depletion described above.6PubMed Central. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved High gastrin and low acid are two sides of the same coin: when the stomach senses less acid, it ramps up gastrin production to try to compensate, and that elevated gastrin has its own effects on bone and tissue throughout the gut.
The absolute increase in fracture risk appears modest for most people. But for older adults who already have thin bones, or for anyone taking omeprazole alongside other risk factors like steroid use or a sedentary lifestyle, it adds up. Some guidelines now recommend periodic bone density screening for patients on PPIs for extended periods.7PubMed Central. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature
Infections Your Stomach Acid Used to Prevent
Stomach acid is one of your body’s first lines of defense against foodborne pathogens. Lowering it chronically opens the door to infections that a normal stomach would handle. The two categories that get the most attention are gut infections from swallowed bacteria and Clostridioides difficile (C. diff) infection.
A meta-analysis of community-acquired gut infections found that PPI users had roughly four times the odds of developing infections from bacteria like Salmonella and Campylobacter compared to nonusers.8PubMed. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis That is a large relative increase, though the baseline risk of these infections in most people is low. Still, if you are traveling to areas with higher rates of foodborne illness, being on a PPI means your safety margin is thinner.
C. diff is a more serious concern, especially in hospitalized or elderly patients. One hospital-based study found that patients on omeprazole were about twice as likely to develop C. diff infection compared to controls.9PubMed Central. Association between omeprazole use and Clostridium difficile infection among hospitalized patients: A case-control study of the Saudi population Recent research using gut models suggests this happens because the pH change itself promotes C. diff growth rather than the drug interacting directly with gut bacteria.10PubMed Central. Proton-pump inhibitors increase C. difficile infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model In plain terms, C. diff thrives in a less acidic gut, and PPIs deliver exactly that environment.
Bacterial Overgrowth in the Small Intestine
Your small intestine is supposed to have relatively few bacteria compared to your colon. When too many colonize it, the result is called small intestinal bacterial overgrowth, or SIBO, which can cause bloating, gas, diarrhea, and nutrient malabsorption. Because stomach acid normally keeps the bacterial population of the upper gut in check, suppressing it with PPIs can tip the balance.
Studies have found widely varying rates. One study detected SIBO in half of PPI users compared to just 6% of healthy controls.11PubMed. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy Another found a rate of about 13% in PPI-only patients.12PubMed Central. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics The huge difference likely reflects different testing methods and patient populations. But the pattern is consistent: long-term PPI use raises SIBO risk, and the risk appears to grow with longer treatment duration.
If you have been on omeprazole for a while and experience persistent bloating or loose stools that are not explained by other causes, SIBO is worth discussing with your doctor. It is treatable, usually with a course of antibiotics, but the underlying cause (the acid suppression) may lead to recurrence if the PPI continues.
Changes to the Gut Microbiome
Beyond SIBO, omeprazole reshapes the broader community of microbes living throughout your digestive tract. A large study including twin pairs found that PPI users had lower microbial diversity overall and a marked increase in bacteria that normally live in the mouth and upper throat, particularly Streptococcus species.13Gut. Proton pump inhibitors alter the composition of the gut microbiota The leading explanation is straightforward: the acid barrier between the upper and lower digestive tract weakens, allowing oral bacteria to colonize the gut.
Shorter-term studies have shown that even a week of omeprazole can shift bacterial populations, though some changes revert once the drug is stopped.14PubMed Central. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore Higher doses appear to reduce microbial diversity more than lower doses.15PubMed. The effect of omeprazole treatment on the gut microflora and neutrophil function What these microbiome shifts mean for long-term health is still being worked out. The overgrowth of Streptococcus in the gut has been proposed as one mechanism behind the increased pneumonia risk seen in PPI users, since these bacteria can migrate between the gut, oral cavity, and respiratory tract.16PubMed Central. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study
Pneumonia Risk
The connection between acid suppression and pneumonia may seem strange until you consider the bacterial migration just described. When stomach acidity drops, pathogens from the mouth and upper gut can survive and multiply in the stomach. From there, they can reach the lungs through micro-aspiration, which is the medical term for accidentally breathing in tiny amounts of stomach contents, something that happens in small quantities during sleep even in healthy people.17JAMA. Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs With the normal acid barrier weakened, the bacteria arriving in the lungs are more numerous and more diverse. The risk increase appears to be most pronounced in the first few weeks after starting a PPI, but some residual elevation persists with continued use.
Kidney Concerns
Omeprazole has been linked to both acute interstitial nephritis, an inflammatory kidney condition, and a slower progression toward chronic kidney disease.18PubMed Central. Molecular pathways driving omeprazole nephrotoxicity Acute interstitial nephritis is rare and usually reversible once the drug is stopped, but it can go undetected if kidney function is not monitored. The chronic kidney disease association is more controversial because the studies showing it are observational, meaning they cannot prove cause and effect. People who take PPIs long-term tend to be older and sicker on average, which makes it hard to isolate the drug’s contribution. Still, the signal has been consistent enough across studies that periodic kidney function checks are prudent for long-term users.
The Dementia Question
Headlines linking PPIs to dementia have caused significant alarm, but the evidence here is genuinely mixed. A large German study of older adults found that regular PPI users had roughly a 50% higher hazard of developing dementia, with similar numbers for omeprazole and pantoprazole.19JAMA Neurology. Association of Proton Pump Inhibitors With Risk of Dementia That sounds alarming, but the study was observational, and the same confounding issues apply: PPI users tend to be older and have more health problems.
A more recent Mendelian randomization study, a design that uses genetic variation to try to tease out cause and effect, found no overall causal link between omeprazole and dementia broadly.20PubMed. Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study It did suggest a possible increased risk for one rare subtype, frontotemporal dementia, and a decreased risk for another, vascular dementia. The proposed mechanisms, including interference with brain protein clearance, have been explored in lab studies and animal models but remain unproven in humans.21PubMed Central. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences The honest summary is that the dementia link is weaker than early headlines suggested, but the question is not fully settled.
Cardiovascular and Endothelial Effects
PPIs may affect blood vessel function through a mechanism unrelated to acid: they appear to inhibit an enzyme involved in producing nitric oxide, the molecule that tells blood vessels to relax. A cross-sectional study of long-term PPI users found evidence of impaired endothelial function and altered nitric oxide metabolism.22PubMed. Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross-sectional study Whether this translates to more heart attacks and strokes over time is unclear, but the mechanism is biologically plausible and adds another reason to avoid unnecessary long-term use.
The Clopidogrel Interaction
If you take clopidogrel, a common blood thinner prescribed after heart procedures, the interaction with omeprazole deserves specific attention. Both drugs are processed by the same liver enzyme (CYP2C19), and omeprazole can compete for that enzyme, potentially reducing how well clopidogrel works. Pharmacology studies have confirmed that omeprazole reduces the antiplatelet effect of clopidogrel in lab measurements.23PubMed Central. Clinical relevance of clopidogrel-proton pump inhibitors interaction
The clinical picture is more nuanced. The only large randomized trial testing this combination found similar rates of cardiovascular events whether patients received omeprazole or placebo alongside clopidogrel, while omeprazole did reduce gastrointestinal bleeding.24PubMed. Clopidogrel with or without omeprazole in coronary artery disease However, a real-world study found that patients who either carried certain genetic variants affecting CYP2C19 or were taking omeprazole or esomeprazole had significantly more vascular events than those without either factor.25European Heart Journal. CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel – a real-world study The practical takeaway: if you need both a PPI and clopidogrel, many cardiologists will switch you to pantoprazole or another PPI that interferes less with this enzyme.
Stomach Polyps and Tissue Changes
Long-term omeprazole use causes visible changes to the stomach lining. The most common are fundic gland polyps, small benign growths in the upper part of the stomach. These develop because sustained low acid triggers elevated gastrin, which in turn causes parietal cells to bulge into the gland lumen, eventually forming cysts that can enlarge into polyps.26Gut and Liver. Proton Pump Inhibitor-Related Gastric Mucosal Changes The reassuring part: these polyps are almost always benign and tend to shrink or disappear after the PPI is stopped. In one documented case, a patient who had developed multiple polyps after a decade of PPI use saw obvious regression within six months of discontinuation.27PubMed Central. Fundic Gland Polyposis Associated with Proton-Pump Inhibitor Use
If polyps are found during an endoscopy and you have been on a PPI for years, the finding alone is not cause for panic. Your gastroenterologist will typically biopsy them to confirm they are the benign fundic gland type and may discuss whether the PPI is still necessary.
Rebound Acid When You Try to Stop
One of the most practically frustrating side effects of long-term omeprazole is what happens when you stop taking it. Your stomach compensates for months of suppressed acid by growing extra acid-producing cells and raising gastrin levels. When the drug is removed, all that extra capacity fires at once, and you can end up producing more acid than you did before you ever started the medication. In healthy volunteers without any underlying acid disorder, this rebound caused new gastrointestinal symptoms in roughly 40 to 50% of subjects.28PubMed Central. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?
An earlier study in people without H. pylori infection measured acid output directly and found that basal acid production was 82% higher two weeks after stopping omeprazole than it had been before treatment began.29PubMed. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status This rebound creates a vicious cycle: you stop the drug, feel worse than ever, and conclude you truly need it. Many people restart the PPI thinking their original condition has come back, when what they are actually experiencing is a withdrawal phenomenon that would resolve on its own if managed through a gradual taper.
How to Step Down Safely
An evidence-based guideline on deprescribing PPIs recommends that adults who have been on omeprazole for at least four weeks for heartburn or mild-to-moderate reflux, and whose symptoms have resolved, should consider reducing the dose, switching to on-demand use, or stopping entirely.30PubMed Central. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline The recommendation does not apply to people with Barrett’s esophagus, severe erosive esophagitis, or a history of bleeding ulcers, for whom ongoing acid suppression may be essential.
The typical approach is to halve the dose for two to four weeks, then switch to every-other-day dosing, then stop. Having an antacid or an H2 blocker like famotidine on hand during the taper can help manage rebound symptoms without restarting the PPI. Most people find the rebound settles within a few weeks.
Vulnerabilities in Children and Older Adults
The side-effect profile can look different at the extremes of age. A systematic review of PPI safety in children found adverse effects in about 7% of the pediatric population studied. The most common were respiratory tract complications, gastrointestinal issues, and urinary tract infections. Asthma risk stood out: children who started PPIs before six months of age had roughly an 83% higher hazard of developing asthma, and children started between six months and two years had a similar elevation.31PubMed Central. Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review The mechanism is not proven, but the altered microbiome and reduced acid barrier during a critical window of immune development are plausible contributors.
In older adults, the concerns stack: higher baseline fracture risk plus PPI-associated bone effects, more medications creating more interaction potential, declining kidney function that may be further stressed, and greater vulnerability to nutrient deficiencies. Polypharmacy reviews in elderly patients frequently identify a PPI that was started years ago for an indication that no longer exists, and stopping it often goes smoothly with a proper taper.
Over-the-Counter Use and Self-Prescribing Patterns
Omeprazole is available without a prescription in many countries, and most people who buy it over the counter use it responsibly. In a study tracking OTC omeprazole purchasers, only about 3% took more than 14 consecutive doses without consulting a physician, and most had contact with a doctor about their heartburn at some point during the study period. After three months, over 40% no longer had recurring heartburn and had presumably stopped on their own. The concern is not the majority but the minority who drift into months or years of daily use without medical oversight, missing the opportunity to check for nutrient levels, kidney function, or whether the original problem even requires ongoing treatment.